MNMD Company Profile and Key Details

MNMD has shown sold momentum, gaining 7.06% over the past week and 22.61% over the past quarter, though year-to-date performance is up 12.17%. Short-term trend indicators are bearishly aligned (SMA20 11.13%, SMA50 19.53%, SMA200 55.68%). The stock’s 14-day RSI is 65.25 (firm momentum), while the ATR of 0.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.77% below its high and over 219.57% above its low. Average 10-day trading volume of 1.25 million shares is below the 3-month average of 1.83 million, indicating normal recent market interest.

Mind Medicine (MindMed) Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 12.11%. Wall Street analysts project EPS growth of -1.0% annually over the next five years. The latest quarter delivered EPS of -$0.78. The next quarter is forecast at -$0.49. Next year's EPS is expected at $16.97. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $61.00 to $16.00. The high target offers 248.37% upside. The low target suggests -8.62% downside. The mean target is $31.25. This offers 78.47% upside. Mind Medicine (MindMed) Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 50.0%. The prior quarter beat by 31.58%. Over the last six quarters, Apple has recorded several small beats. These include 60.0% in August 13, 2024.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) closed at $17.51 USD, gaining $0.06 (0.34%) from the previous close of $17.45. The stock is currently within 5% of its 52-week high $4.70 and $18.42. With a market capitalization of about $1.32 billion, Mind Medicine (MindMed) Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.62). Key stats such as the average daily volume over the past year has been around 2.53 million shares, volume is running light vs its 52-week average. Headquartered in Vancouver, BC, Mind Medicine (MindMed) Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Barrow, the company employs approximately 74 people and listed since November 15, 2016. Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.

Mind Medicine (MindMed) Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading above this model’s fair value.

Mind Medicine (MindMed) Inc. has 76.09 million shares outstanding. The public float is 70.25 million shares, elevated short interest at 13.87% of float. This equals 10.47 million shares. The short ratio is 8.56 days. Institutional investors hold 56.19% of the float. Insiders own 0.84%. Barrow Robert holds 778.48 thousand shares, Karlin Daniel has 425.02 thousand shares and Karlin Dan has 338.01 thousand shares. Over the past six months, insider transactions show net selling. They sold 87.45 thousand shares across 6 transactions.

Mind Medicine (MindMed) Inc. trades at a P/E ratio of -8.95, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 11.52 reflecting a rich premium to book value. The P/FCF stands at -11.61, also below market averages. Compared to sector medians, Mind Medicine (MindMed) Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are up 12.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Mind Medicine (MindMed) Inc. trading at a premium to the broader market with a P/E of -8.95. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $31.91, suggesting 81.1% upside. Our AI forecast model points to short-term weakness (-1.19% over two weeks), a medium-term rise (60.9% over three months), and a longer-term gain (19.86% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Mind Medicine (MindMed) Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.19%, with price expected at $17.41 by March 11, 2026, within a range of $16.68 to $18.10 3-Month Outlook: Projected rise of 60.9%, reaching $28.35 by May 26, 2026, with a range of $27.62 to $29.30. 1-Year Outlook: Projected gain of 19.86%, with price at $21.12 by February 25, 2027, within a range of $20.32 to $21.87.